Literature DB >> 26307433

Potentiation of cytokine-induced proliferation of human Natural Killer cells by intravenous immunoglobulin G.

Andrew C Issekutz1, Beata Derfalvi2, Fabian Käsermann3, Derek Rowter2.   

Abstract

Intravenous IgG (IVIG) therapy can be used for immunomodulation. IL-2 is an immunoregulatory cytokine. We evaluated IVIG modulation of human blood lymphocyte response to IL-2 and other cytokines. Neither IVIG nor low concentrations of IL-2 (3-30U/ml) induced lymphocyte proliferation, but in combination they synergistically enhanced proliferation of NK cells. The CD56(bright) cells expanded more than CD56(dim) NK cells, with 90% of NK cells dividing up to 8 generations by day 6, while <8% of T cells divided. IVIG also potentiated NK cell proliferation with IL-12, IL-15 and IL-18. The IVIG+cytokine-expanded NK cells were less cytotoxic for K562 cells, than NK cells with cytokine alone. IVIG also enhanced interferon-γ production with IL-2, IL-12 and IL-18. In conclusion, IVIG selectively potentiates NK cell proliferation and interferon-γ secretion with IL-2, IL-12, IL-15 and IL-18 in vitro. These findings warrant evaluation in vivo in relation to NK cells and the immunoregulatory actions of IVIG.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytokine; IgG; Immunomodulation; NK lymphocyte; Natural killer cell

Mesh:

Substances:

Year:  2015        PMID: 26307433     DOI: 10.1016/j.clim.2015.08.005

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  2 in total

Review 1.  Potentiation of Natural Killer Cells for Cancer Immunotherapy: A Review of Literature.

Authors:  Lacy E Lowry; William A Zehring
Journal:  Front Immunol       Date:  2017-09-01       Impact factor: 7.561

2.  High Dose Intravenous IgG Therapy Modulates Multiple NK Cell and T Cell Functions in Patients With Immune Dysregulation.

Authors:  Sarah M McAlpine; Sarah E Roberts; John J Heath; Fabian Käsermann; Andrew C Issekutz; Thomas B Issekutz; Beata Derfalvi
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.